JP2021522189A - 上皮の生存と体表面の再構成を高めるための高分子量ヒアルロン酸 - Google Patents
上皮の生存と体表面の再構成を高めるための高分子量ヒアルロン酸 Download PDFInfo
- Publication number
- JP2021522189A JP2021522189A JP2020557324A JP2020557324A JP2021522189A JP 2021522189 A JP2021522189 A JP 2021522189A JP 2020557324 A JP2020557324 A JP 2020557324A JP 2020557324 A JP2020557324 A JP 2020557324A JP 2021522189 A JP2021522189 A JP 2021522189A
- Authority
- JP
- Japan
- Prior art keywords
- repair
- replenishment method
- composition
- hyaluronic acid
- replenishment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920002674 hyaluronan Polymers 0.000 title claims abstract description 160
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 title claims abstract description 151
- 229960003160 hyaluronic acid Drugs 0.000 title claims abstract description 140
- 230000004083 survival effect Effects 0.000 title description 3
- 238000000034 method Methods 0.000 claims abstract description 168
- 239000000203 mixture Substances 0.000 claims abstract description 161
- 230000008439 repair process Effects 0.000 claims abstract description 139
- 210000000981 epithelium Anatomy 0.000 claims abstract description 43
- 206010003645 Atopy Diseases 0.000 claims abstract description 28
- 239000013589 supplement Substances 0.000 claims abstract 3
- 210000001508 eye Anatomy 0.000 claims description 76
- 239000012530 fluid Substances 0.000 claims description 49
- 239000003755 preservative agent Substances 0.000 claims description 47
- 206010020751 Hypersensitivity Diseases 0.000 claims description 34
- 201000002287 Keratoconus Diseases 0.000 claims description 29
- 239000012867 bioactive agent Substances 0.000 claims description 27
- 210000001519 tissue Anatomy 0.000 claims description 27
- 239000003889 eye drop Substances 0.000 claims description 24
- 230000000694 effects Effects 0.000 claims description 23
- 230000002335 preservative effect Effects 0.000 claims description 23
- 210000004027 cell Anatomy 0.000 claims description 21
- 239000002253 acid Substances 0.000 claims description 20
- -1 bechrometazone Chemical compound 0.000 claims description 20
- 208000026935 allergic disease Diseases 0.000 claims description 19
- 210000003491 skin Anatomy 0.000 claims description 19
- 239000012459 cleaning agent Substances 0.000 claims description 15
- 239000002955 immunomodulating agent Substances 0.000 claims description 15
- 229940121354 immunomodulator Drugs 0.000 claims description 15
- 239000000126 substance Substances 0.000 claims description 15
- 230000000254 damaging effect Effects 0.000 claims description 13
- 230000000622 irritating effect Effects 0.000 claims description 13
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 12
- 239000000853 adhesive Substances 0.000 claims description 12
- 230000001070 adhesive effect Effects 0.000 claims description 12
- 201000008937 atopic dermatitis Diseases 0.000 claims description 12
- 239000006071 cream Substances 0.000 claims description 12
- 230000001965 increasing effect Effects 0.000 claims description 12
- 230000001404 mediated effect Effects 0.000 claims description 12
- 229920002683 Glycosaminoglycan Polymers 0.000 claims description 10
- 208000010668 atopic eczema Diseases 0.000 claims description 10
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 9
- 229930105110 Cyclosporin A Natural products 0.000 claims description 9
- 108010036949 Cyclosporine Proteins 0.000 claims description 9
- 229960001265 ciclosporin Drugs 0.000 claims description 9
- 230000006378 damage Effects 0.000 claims description 9
- 230000002584 immunomodulator Effects 0.000 claims description 9
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 8
- 239000002537 cosmetic Substances 0.000 claims description 8
- 150000003180 prostaglandins Chemical class 0.000 claims description 8
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 8
- 208000024891 symptom Diseases 0.000 claims description 8
- 230000000813 microbial effect Effects 0.000 claims description 7
- 206010010741 Conjunctivitis Diseases 0.000 claims description 6
- 208000024780 Urticaria Diseases 0.000 claims description 6
- 230000000172 allergic effect Effects 0.000 claims description 6
- 239000000739 antihistaminic agent Substances 0.000 claims description 6
- 208000006673 asthma Diseases 0.000 claims description 6
- 239000000872 buffer Substances 0.000 claims description 6
- 210000000170 cell membrane Anatomy 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 239000003599 detergent Substances 0.000 claims description 6
- 210000003238 esophagus Anatomy 0.000 claims description 6
- 210000003630 histaminocyte Anatomy 0.000 claims description 6
- 230000009610 hypersensitivity Effects 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 239000006210 lotion Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 150000003431 steroids Chemical class 0.000 claims description 6
- 208000012657 Atopic disease Diseases 0.000 claims description 5
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 5
- 239000003242 anti bacterial agent Substances 0.000 claims description 5
- 229940088710 antibiotic agent Drugs 0.000 claims description 5
- 229940124447 delivery agent Drugs 0.000 claims description 5
- 239000006196 drop Substances 0.000 claims description 5
- 239000000499 gel Substances 0.000 claims description 5
- 210000004209 hair Anatomy 0.000 claims description 5
- 230000002209 hydrophobic effect Effects 0.000 claims description 5
- 239000003018 immunosuppressive agent Substances 0.000 claims description 5
- 229960000598 infliximab Drugs 0.000 claims description 5
- 239000000243 solution Substances 0.000 claims description 5
- 229960001967 tacrolimus Drugs 0.000 claims description 5
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims description 5
- 230000000699 topical effect Effects 0.000 claims description 5
- VAZJLPXFVQHDFB-UHFFFAOYSA-N 1-(diaminomethylidene)-2-hexylguanidine Polymers CCCCCCN=C(N)N=C(N)N VAZJLPXFVQHDFB-UHFFFAOYSA-N 0.000 claims description 4
- 108010002350 Interleukin-2 Proteins 0.000 claims description 4
- 102000000588 Interleukin-2 Human genes 0.000 claims description 4
- 229920002413 Polyhexanide Polymers 0.000 claims description 4
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 4
- 102100040247 Tumor necrosis factor Human genes 0.000 claims description 4
- 201000009961 allergic asthma Diseases 0.000 claims description 4
- 201000010105 allergic rhinitis Diseases 0.000 claims description 4
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 4
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 claims description 4
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 4
- 230000000977 initiatory effect Effects 0.000 claims description 4
- 230000002503 metabolic effect Effects 0.000 claims description 4
- 210000000214 mouth Anatomy 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 229940094443 oxytocics prostaglandins Drugs 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 239000000344 soap Substances 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims description 4
- 238000011200 topical administration Methods 0.000 claims description 4
- 210000003932 urinary bladder Anatomy 0.000 claims description 4
- 210000001215 vagina Anatomy 0.000 claims description 4
- 229920000742 Cotton Polymers 0.000 claims description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 3
- 108010008165 Etanercept Proteins 0.000 claims description 3
- 102000008070 Interferon-gamma Human genes 0.000 claims description 3
- 108010074328 Interferon-gamma Proteins 0.000 claims description 3
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 claims description 3
- 229910019142 PO4 Inorganic materials 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 3
- 239000002168 alkylating agent Substances 0.000 claims description 3
- 229940100198 alkylating agent Drugs 0.000 claims description 3
- 239000005557 antagonist Substances 0.000 claims description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 3
- 229940125715 antihistaminic agent Drugs 0.000 claims description 3
- 230000003078 antioxidant effect Effects 0.000 claims description 3
- 210000001072 colon Anatomy 0.000 claims description 3
- 239000003792 electrolyte Substances 0.000 claims description 3
- 210000003560 epithelium corneal Anatomy 0.000 claims description 3
- 229960000403 etanercept Drugs 0.000 claims description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 3
- 229940046732 interleukin inhibitors Drugs 0.000 claims description 3
- 150000002500 ions Chemical class 0.000 claims description 3
- 150000002632 lipids Chemical group 0.000 claims description 3
- 210000004877 mucosa Anatomy 0.000 claims description 3
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 3
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 3
- 229960002930 sirolimus Drugs 0.000 claims description 3
- 239000003381 stabilizer Substances 0.000 claims description 3
- 230000000087 stabilizing effect Effects 0.000 claims description 3
- 210000003437 trachea Anatomy 0.000 claims description 3
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 claims description 3
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 claims description 3
- WSWCOQWTEOXDQX-MQQKCMAXSA-M (E,E)-sorbate Chemical compound C\C=C\C=C\C([O-])=O WSWCOQWTEOXDQX-MQQKCMAXSA-M 0.000 claims description 2
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 claims description 2
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 claims description 2
- XHVAWZZCDCWGBK-WYRLRVFGSA-M Aurothioglucose Chemical compound OC[C@H]1O[C@H](S[Au])[C@H](O)[C@@H](O)[C@@H]1O XHVAWZZCDCWGBK-WYRLRVFGSA-M 0.000 claims description 2
- 241000195940 Bryophyta Species 0.000 claims description 2
- 101150071146 COX2 gene Proteins 0.000 claims description 2
- 101100114534 Caenorhabditis elegans ctc-2 gene Proteins 0.000 claims description 2
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 claims description 2
- VPGRYOFKCNULNK-ACXQXYJUSA-N Deoxycorticosterone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)COC(=O)C)[C@@]1(C)CC2 VPGRYOFKCNULNK-ACXQXYJUSA-N 0.000 claims description 2
- 241000021559 Dicerandra Species 0.000 claims description 2
- 102000003996 Interferon-beta Human genes 0.000 claims description 2
- 108090000467 Interferon-beta Proteins 0.000 claims description 2
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims description 2
- 208000007811 Latex Hypersensitivity Diseases 0.000 claims description 2
- 235000010654 Melissa officinalis Nutrition 0.000 claims description 2
- 239000004909 Moisturizer Substances 0.000 claims description 2
- 206010030113 Oedema Diseases 0.000 claims description 2
- 101150000187 PTGS2 gene Proteins 0.000 claims description 2
- 206010039251 Rubber sensitivity Diseases 0.000 claims description 2
- 101000935814 Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720) Periplasmic beta-glucosidase Proteins 0.000 claims description 2
- 229940123155 T cell inhibitor Drugs 0.000 claims description 2
- 229960002964 adalimumab Drugs 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- 229960002478 aldosterone Drugs 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 210000000436 anus Anatomy 0.000 claims description 2
- 230000003796 beauty Effects 0.000 claims description 2
- 229940125388 beta agonist Drugs 0.000 claims description 2
- 229960002537 betamethasone Drugs 0.000 claims description 2
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims description 2
- 235000014121 butter Nutrition 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 210000004534 cecum Anatomy 0.000 claims description 2
- 210000003679 cervix uteri Anatomy 0.000 claims description 2
- 229960004926 chlorobutanol Drugs 0.000 claims description 2
- 239000000812 cholinergic antagonist Substances 0.000 claims description 2
- 229960003290 cortisone acetate Drugs 0.000 claims description 2
- 239000006184 cosolvent Substances 0.000 claims description 2
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims description 2
- 239000007933 dermal patch Substances 0.000 claims description 2
- 229960004486 desoxycorticosterone acetate Drugs 0.000 claims description 2
- 229960003957 dexamethasone Drugs 0.000 claims description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 2
- 239000003974 emollient agent Substances 0.000 claims description 2
- SYWHXTATXSMDSB-GSLJADNHSA-N fludrocortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O SYWHXTATXSMDSB-GSLJADNHSA-N 0.000 claims description 2
- 229960003336 fluorocortisol acetate Drugs 0.000 claims description 2
- 239000006260 foam Substances 0.000 claims description 2
- 230000007614 genetic variation Effects 0.000 claims description 2
- 210000004392 genitalia Anatomy 0.000 claims description 2
- 239000003862 glucocorticoid Substances 0.000 claims description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052737 gold Inorganic materials 0.000 claims description 2
- 239000010931 gold Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 230000036541 health Effects 0.000 claims description 2
- 230000001861 immunosuppressant effect Effects 0.000 claims description 2
- 239000012535 impurity Substances 0.000 claims description 2
- 230000009027 insemination Effects 0.000 claims description 2
- 229960003130 interferon gamma Drugs 0.000 claims description 2
- 229960001388 interferon-beta Drugs 0.000 claims description 2
- 235000015110 jellies Nutrition 0.000 claims description 2
- 239000008274 jelly Substances 0.000 claims description 2
- 229960004958 ketotifen Drugs 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 201000005391 latex allergy Diseases 0.000 claims description 2
- 239000000865 liniment Substances 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 229960004584 methylprednisolone Drugs 0.000 claims description 2
- DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 claims description 2
- 229960004023 minocycline Drugs 0.000 claims description 2
- 230000001333 moisturizer Effects 0.000 claims description 2
- 235000011929 mousse Nutrition 0.000 claims description 2
- 239000002324 mouth wash Substances 0.000 claims description 2
- 210000004400 mucous membrane Anatomy 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 230000003204 osmotic effect Effects 0.000 claims description 2
- 210000003101 oviduct Anatomy 0.000 claims description 2
- 239000007800 oxidant agent Substances 0.000 claims description 2
- 230000001590 oxidative effect Effects 0.000 claims description 2
- 125000005430 oxychloro group Chemical group 0.000 claims description 2
- 239000006072 paste Substances 0.000 claims description 2
- 230000035699 permeability Effects 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 239000008363 phosphate buffer Substances 0.000 claims description 2
- 231100000614 poison Toxicity 0.000 claims description 2
- 229960005205 prednisolone Drugs 0.000 claims description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 2
- 229960004618 prednisone Drugs 0.000 claims description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 2
- 125000001453 quaternary ammonium group Chemical group 0.000 claims description 2
- 210000000664 rectum Anatomy 0.000 claims description 2
- 229960001860 salicylate Drugs 0.000 claims description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 claims description 2
- 230000028327 secretion Effects 0.000 claims description 2
- 239000002453 shampoo Substances 0.000 claims description 2
- 229960001922 sodium perborate Drugs 0.000 claims description 2
- YKLJGMBLPUQQOI-UHFFFAOYSA-M sodium;oxidooxy(oxo)borane Chemical compound [Na+].[O-]OB=O YKLJGMBLPUQQOI-UHFFFAOYSA-M 0.000 claims description 2
- 229940075554 sorbate Drugs 0.000 claims description 2
- 210000002784 stomach Anatomy 0.000 claims description 2
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims description 2
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims description 2
- 229960001940 sulfasalazine Drugs 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 229960000278 theophylline Drugs 0.000 claims description 2
- 229960005294 triamcinolone Drugs 0.000 claims description 2
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims description 2
- 210000004291 uterus Anatomy 0.000 claims description 2
- 229960005486 vaccine Drugs 0.000 claims description 2
- 230000002792 vascular Effects 0.000 claims description 2
- 239000000047 product Substances 0.000 claims 7
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 2
- 229960000686 benzalkonium chloride Drugs 0.000 claims 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims 2
- 239000000428 dust Substances 0.000 claims 2
- 201000001564 eosinophilic gastroenteritis Diseases 0.000 claims 2
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 claims 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims 1
- 206010006474 Bronchopulmonary aspergillosis allergic Diseases 0.000 claims 1
- 208000001840 Dandruff Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010052140 Eye pruritus Diseases 0.000 claims 1
- 241000238631 Hexapoda Species 0.000 claims 1
- 229940124150 Lymphocyte inhibitor Drugs 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims 1
- 208000036071 Rhinorrhea Diseases 0.000 claims 1
- 206010039101 Rhinorrhoea Diseases 0.000 claims 1
- 206010048908 Seasonal allergy Diseases 0.000 claims 1
- 206010040744 Sinus headache Diseases 0.000 claims 1
- 206010042674 Swelling Diseases 0.000 claims 1
- 208000006778 allergic bronchopulmonary aspergillosis Diseases 0.000 claims 1
- 208000030961 allergic reaction Diseases 0.000 claims 1
- 239000003899 bactericide agent Substances 0.000 claims 1
- 239000000022 bacteriostatic agent Substances 0.000 claims 1
- 210000005069 ears Anatomy 0.000 claims 1
- 229940009662 edetate Drugs 0.000 claims 1
- 206010057271 eosinophilic colitis Diseases 0.000 claims 1
- 239000004744 fabric Substances 0.000 claims 1
- 210000003608 fece Anatomy 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 210000002429 large intestine Anatomy 0.000 claims 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims 1
- 229960000681 leflunomide Drugs 0.000 claims 1
- 239000002574 poison Substances 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 206010041232 sneezing Diseases 0.000 claims 1
- 230000003637 steroidlike Effects 0.000 claims 1
- 230000008961 swelling Effects 0.000 claims 1
- 230000007812 deficiency Effects 0.000 abstract description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 11
- 230000009931 harmful effect Effects 0.000 abstract description 2
- 150000003839 salts Chemical class 0.000 description 29
- 230000005856 abnormality Effects 0.000 description 25
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 22
- 238000001356 surgical procedure Methods 0.000 description 22
- 229940099552 hyaluronan Drugs 0.000 description 20
- 238000011282 treatment Methods 0.000 description 20
- 229940012356 eye drops Drugs 0.000 description 19
- 230000004054 inflammatory process Effects 0.000 description 19
- 206010061218 Inflammation Diseases 0.000 description 18
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 17
- 206010013774 Dry eye Diseases 0.000 description 17
- 230000006870 function Effects 0.000 description 12
- 208000014674 injury Diseases 0.000 description 12
- 230000000007 visual effect Effects 0.000 description 12
- 102000004127 Cytokines Human genes 0.000 description 11
- 108090000695 Cytokines Proteins 0.000 description 11
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 11
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 11
- 210000002744 extracellular matrix Anatomy 0.000 description 11
- 230000028993 immune response Effects 0.000 description 11
- 239000002876 beta blocker Substances 0.000 description 10
- 229940097320 beta blocking agent Drugs 0.000 description 10
- 230000007794 irritation Effects 0.000 description 10
- 230000007815 allergy Effects 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 206010061598 Immunodeficiency Diseases 0.000 description 8
- 208000029462 Immunodeficiency disease Diseases 0.000 description 8
- 208000027418 Wounds and injury Diseases 0.000 description 8
- 210000004087 cornea Anatomy 0.000 description 8
- 230000007813 immunodeficiency Effects 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 102100032912 CD44 antigen Human genes 0.000 description 7
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 210000004698 lymphocyte Anatomy 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 6
- 230000008827 biological function Effects 0.000 description 6
- 229940072322 hylan Drugs 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 230000008733 trauma Effects 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 5
- 208000010412 Glaucoma Diseases 0.000 description 5
- 102000013691 Interleukin-17 Human genes 0.000 description 5
- 108050003558 Interleukin-17 Proteins 0.000 description 5
- 208000003251 Pruritus Diseases 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 5
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 210000002919 epithelial cell Anatomy 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000000770 proinflammatory effect Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 241000282412 Homo Species 0.000 description 4
- 108090000320 Hyaluronan Synthases Proteins 0.000 description 4
- 102000000589 Interleukin-1 Human genes 0.000 description 4
- 108010002352 Interleukin-1 Proteins 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 230000012292 cell migration Effects 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 230000013632 homeostatic process Effects 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 150000007523 nucleic acids Chemical group 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000029663 wound healing Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- 102000003918 Hyaluronan Synthases Human genes 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 102000004388 Interleukin-4 Human genes 0.000 description 3
- 108090000978 Interleukin-4 Proteins 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000013566 allergen Substances 0.000 description 3
- 201000009310 astigmatism Diseases 0.000 description 3
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000002016 disaccharides Chemical group 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 208000030533 eye disease Diseases 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 229940028885 interleukin-4 Drugs 0.000 description 3
- 206010023332 keratitis Diseases 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 239000005022 packaging material Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 239000003642 reactive oxygen metabolite Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 210000005125 simple columnar epithelium Anatomy 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 238000012876 topography Methods 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 2
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 102000014156 AMP-Activated Protein Kinases Human genes 0.000 description 2
- 108010011376 AMP-Activated Protein Kinases Proteins 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 206010057380 Allergic keratitis Diseases 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 2
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 2
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 2
- 102100036150 C-X-C motif chemokine 5 Human genes 0.000 description 2
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 2
- 208000002177 Cataract Diseases 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 101000947186 Homo sapiens C-X-C motif chemokine 5 Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 208000001718 Immediate Hypersensitivity Diseases 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 102000004890 Interleukin-8 Human genes 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 2
- 101150063393 Tmem79 gene Proteins 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 206010045240 Type I hypersensitivity Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 229960002274 atenolol Drugs 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 210000000795 conjunctiva Anatomy 0.000 description 2
- 210000003239 corneal fibroblast Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000007705 epithelial mesenchymal transition Effects 0.000 description 2
- 210000001723 extracellular space Anatomy 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 210000005119 human aortic smooth muscle cell Anatomy 0.000 description 2
- 229940014041 hyaluronate Drugs 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000002864 infectious keratoconjunctivitis Diseases 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 201000010666 keratoconjunctivitis Diseases 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 238000013160 medical therapy Methods 0.000 description 2
- 238000010197 meta-analysis Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 229960004255 nadolol Drugs 0.000 description 2
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- 210000001331 nose Anatomy 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 210000001539 phagocyte Anatomy 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 229940012957 plasmin Drugs 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000000611 regression analysis Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 108010038379 sargramostim Proteins 0.000 description 2
- 230000009291 secondary effect Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000021 stimulant Substances 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 230000007306 turnover Effects 0.000 description 2
- DZGWFCGJZKJUFP-UHFFFAOYSA-N tyramine Chemical compound NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 2
- 210000001635 urinary tract Anatomy 0.000 description 2
- 229940006076 viscoelastic substance Drugs 0.000 description 2
- 239000003190 viscoelastic substance Substances 0.000 description 2
- CEMAWMOMDPGJMB-UHFFFAOYSA-N (+-)-Oxprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1OCC=C CEMAWMOMDPGJMB-UHFFFAOYSA-N 0.000 description 1
- TWUSDDMONZULSC-HZMBPMFUSA-N (1r,2s)-2-(tert-butylamino)-1-(2,5-dimethoxyphenyl)propan-1-ol Chemical compound COC1=CC=C(OC)C([C@@H](O)[C@H](C)NC(C)(C)C)=C1 TWUSDDMONZULSC-HZMBPMFUSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
- UUOJIACWOAYWEZ-UHFFFAOYSA-N 1-(tert-butylamino)-3-[(2-methyl-1H-indol-4-yl)oxy]propan-2-yl benzoate Chemical compound C1=CC=C2NC(C)=CC2=C1OCC(CNC(C)(C)C)OC(=O)C1=CC=CC=C1 UUOJIACWOAYWEZ-UHFFFAOYSA-N 0.000 description 1
- FJLUATLTXUNBOT-UHFFFAOYSA-N 1-Hexadecylamine Chemical compound CCCCCCCCCCCCCCCCN FJLUATLTXUNBOT-UHFFFAOYSA-N 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 1
- FBMYKMYQHCBIGU-UHFFFAOYSA-N 2-[2-hydroxy-3-[[1-(1h-indol-3-yl)-2-methylpropan-2-yl]amino]propoxy]benzonitrile Chemical compound C=1NC2=CC=CC=C2C=1CC(C)(C)NCC(O)COC1=CC=CC=C1C#N FBMYKMYQHCBIGU-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 102100021407 ATP-dependent RNA helicase DDX18 Human genes 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- HSEMFIZWXHQJAE-UHFFFAOYSA-N Amide-Hexadecanoic acid Natural products CCCCCCCCCCCCCCCC(N)=O HSEMFIZWXHQJAE-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000224489 Amoeba Species 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 102100027161 BRCA2-interacting transcriptional repressor EMSY Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 102100023703 C-C motif chemokine 15 Human genes 0.000 description 1
- 101710098275 C-X-C motif chemokine 10 Proteins 0.000 description 1
- 102100025279 C-X-C motif chemokine 11 Human genes 0.000 description 1
- 101710085500 C-X-C motif chemokine 9 Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- JOATXPAWOHTVSZ-UHFFFAOYSA-N Celiprolol Chemical compound CCN(CC)C(=O)NC1=CC=C(OCC(O)CNC(C)(C)C)C(C(C)=O)=C1 JOATXPAWOHTVSZ-UHFFFAOYSA-N 0.000 description 1
- 102000001326 Chemokine CCL4 Human genes 0.000 description 1
- 108010055165 Chemokine CCL4 Proteins 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 208000028006 Corneal injury Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000000624 Esophageal and Gastric Varices Diseases 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 208000001860 Eye Infections Diseases 0.000 description 1
- 206010015958 Eye pain Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 102100036241 HLA class II histocompatibility antigen, DQ beta 1 chain Human genes 0.000 description 1
- 108010065026 HLA-DQB1 antigen Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 101001057996 Homo sapiens BRCA2-interacting transcriptional repressor EMSY Proteins 0.000 description 1
- 101000978376 Homo sapiens C-C motif chemokine 15 Proteins 0.000 description 1
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 1
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 1
- 101000858060 Homo sapiens C-X-C motif chemokine 11 Proteins 0.000 description 1
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 description 1
- 101001002634 Homo sapiens Interleukin-1 alpha Proteins 0.000 description 1
- 101000961065 Homo sapiens Interleukin-18 receptor 1 Proteins 0.000 description 1
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 1
- 101000763579 Homo sapiens Toll-like receptor 1 Proteins 0.000 description 1
- 101000763537 Homo sapiens Toll-like receptor 10 Proteins 0.000 description 1
- 101000669406 Homo sapiens Toll-like receptor 6 Proteins 0.000 description 1
- 101710128038 Hyaluronan synthase Proteins 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 241000270878 Hyla Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 108700003107 Interleukin-1 Receptor-Like 1 Proteins 0.000 description 1
- 102100036706 Interleukin-1 receptor-like 1 Human genes 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102100039340 Interleukin-18 receptor 1 Human genes 0.000 description 1
- 108010082786 Interleukin-1alpha Proteins 0.000 description 1
- 102000004125 Interleukin-1alpha Human genes 0.000 description 1
- 102000017761 Interleukin-33 Human genes 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 102000000743 Interleukin-5 Human genes 0.000 description 1
- 102100026236 Interleukin-8 Human genes 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010024648 Livedo reticularis Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 101710091439 Major capsid protein 1 Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 102100032118 Mitochondrial outer membrane protein SLC25A46 Human genes 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108091093018 PVT1 Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108010003541 Platelet Activating Factor Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 208000019155 Radiation injury Diseases 0.000 description 1
- 208000035977 Rare disease Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108091006481 SLC25A46 Proteins 0.000 description 1
- 108010011005 STAT6 Transcription Factor Proteins 0.000 description 1
- 102000013968 STAT6 Transcription Factor Human genes 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000007718 Stable Angina Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 102100027010 Toll-like receptor 1 Human genes 0.000 description 1
- 102100027009 Toll-like receptor 10 Human genes 0.000 description 1
- 102100039387 Toll-like receptor 6 Human genes 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 206010056091 Varices oesophageal Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000000674 adrenergic antagonist Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 210000004712 air sac Anatomy 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 230000037446 allergic sensitization Effects 0.000 description 1
- 201000010435 allergic urticaria Diseases 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
- 229960002213 alprenolol Drugs 0.000 description 1
- PAZJSJFMUHDSTF-UHFFFAOYSA-N alprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1CC=C PAZJSJFMUHDSTF-UHFFFAOYSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 159000000032 aromatic acids Chemical class 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 201000007032 bacterial conjunctivitis Diseases 0.000 description 1
- 210000004082 barrier epithelial cell Anatomy 0.000 description 1
- 239000010428 baryte Substances 0.000 description 1
- 229910052601 baryte Inorganic materials 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 102000016967 beta-1 Adrenergic Receptors Human genes 0.000 description 1
- 108010014494 beta-1 Adrenergic Receptors Proteins 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 229960004324 betaxolol Drugs 0.000 description 1
- NWIUTZDMDHAVTP-UHFFFAOYSA-N betaxolol Chemical compound C1=CC(OCC(O)CNC(C)C)=CC=C1CCOCC1CC1 NWIUTZDMDHAVTP-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 229960002781 bisoprolol Drugs 0.000 description 1
- VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 description 1
- 230000004397 blinking Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229960001035 bopindolol Drugs 0.000 description 1
- 229950005341 bucindolol Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229950009770 butaxamine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229960001222 carteolol Drugs 0.000 description 1
- LWAFSWPYPHEXKX-UHFFFAOYSA-N carteolol Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(O)CNC(C)(C)C LWAFSWPYPHEXKX-UHFFFAOYSA-N 0.000 description 1
- 229960002320 celiprolol Drugs 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003822 cell turnover Effects 0.000 description 1
- 102000008373 cell-cell adhesion mediator activity proteins Human genes 0.000 description 1
- 108040002566 cell-cell adhesion mediator activity proteins Proteins 0.000 description 1
- 230000014564 chemokine production Effects 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000011278 co-treatment Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 210000003683 corneal stroma Anatomy 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 208000001309 degenerative myopia Diseases 0.000 description 1
- 230000003413 degradative effect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 210000001047 desmosome Anatomy 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000009189 diving Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000000203 droplet dispensing Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000001159 endocytotic effect Effects 0.000 description 1
- 210000000871 endothelium corneal Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000004890 epithelial barrier function Effects 0.000 description 1
- 208000024170 esophageal varices Diseases 0.000 description 1
- 201000010120 esophageal varix Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000005530 etching Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
- 206010015907 eye allergy Diseases 0.000 description 1
- 208000011323 eye infectious disease Diseases 0.000 description 1
- 210000000720 eyelash Anatomy 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 230000019305 fibroblast migration Effects 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 230000004313 glare Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
- 229940089982 healon Drugs 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003960 inflammatory cascade Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 201000000766 irregular astigmatism Diseases 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 210000004561 lacrimal apparatus Anatomy 0.000 description 1
- 238000013532 laser treatment Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- MPQWSYJGFLADEW-UHFFFAOYSA-N medroxalol Chemical compound C=1C=C2OCOC2=CC=1CCC(C)NCC(O)C1=CC=C(O)C(C(N)=O)=C1 MPQWSYJGFLADEW-UHFFFAOYSA-N 0.000 description 1
- 229950008578 medroxalol Drugs 0.000 description 1
- 210000004175 meibomian gland Anatomy 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000000897 modulatory effect Effects 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- ACTNHJDHMQSOGL-UHFFFAOYSA-N n',n'-dibenzylethane-1,2-diamine Chemical compound C=1C=CC=CC=1CN(CCN)CC1=CC=CC=C1 ACTNHJDHMQSOGL-UHFFFAOYSA-N 0.000 description 1
- NOUUUQMKVOUUNR-UHFFFAOYSA-N n,n'-diphenylethane-1,2-diamine Chemical compound C=1C=CC=CC=1NCCNC1=CC=CC=C1 NOUUUQMKVOUUNR-UHFFFAOYSA-N 0.000 description 1
- DAZSWUUAFHBCGE-KRWDZBQOSA-N n-[(2s)-3-methyl-1-oxo-1-pyrrolidin-1-ylbutan-2-yl]-3-phenylpropanamide Chemical compound N([C@@H](C(C)C)C(=O)N1CCCC1)C(=O)CCC1=CC=CC=C1 DAZSWUUAFHBCGE-KRWDZBQOSA-N 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000002314 neuroinflammatory effect Effects 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229960004570 oxprenolol Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- CMFNMSMUKZHDEY-UHFFFAOYSA-N peroxynitrous acid Chemical compound OON=O CMFNMSMUKZHDEY-UHFFFAOYSA-N 0.000 description 1
- 239000011129 pharmaceutical packaging material Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 229960002508 pindolol Drugs 0.000 description 1
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000003244 pro-oxidative effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000004515 progressive myopia Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010666 regulation of catalytic activity Effects 0.000 description 1
- 230000005139 regulation of hyaluronan biosynthetic process Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 229940116351 sebacate Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000009131 signaling function Effects 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 159000000000 sodium salts Chemical group 0.000 description 1
- 229960002370 sotalol Drugs 0.000 description 1
- ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000012859 sterile filling Methods 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 208000025889 stromal keratitis Diseases 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- 229960004605 timolol Drugs 0.000 description 1
- 230000030968 tissue homeostasis Effects 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 229960003732 tyramine Drugs 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000003741 urothelium Anatomy 0.000 description 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
- 229960002004 valdecoxib Drugs 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0208—Tissues; Wipes; Patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/87—Application Devices; Containers; Packaging
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Birds (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Biomedical Technology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Abstract
【解決手段】
本発明は、被験体の上皮表面にヒアルロン酸を修復または補充するための修復/補充方法であって、組成物を上記被験体の上記上皮表面に局所投与することを含み、上記組成物は、高分子量ヒアルロン酸、高分子量ヒアルロン酸類似体、またはそれらの組み合わせを含み、上記上皮表面は、ヒアルロン酸の量または機能の欠如を有する、修復/補充方法に関する。
Description
諸実施形態では、HMWHA組成物が局所投与される被験体がアトピーを有する。通常、抗体を含む免疫系が抗原と呼ばれる異物から体を守っている。しかし、敏感なヒトでは、特定の物質(アレルゲン)にさらされると免疫系が過剰反応することがある。
諸実施形態では、HMWHA組成物が局所投与される被験体は、円錐角膜(KC)を有する。円錐角膜は進行性の眼疾患であり、通常では円形の角膜が薄くなり、円錐形に隆起し始める。この円錐形状は、光が光感受性網膜に向かう途中で眼に入るときに光を偏向させ、乱視を引き起こす。円錐角膜は片眼または両眼に起こることがあり、10代または20代前半に発症することが多い。
必要に応じて、上記組成物は、1つまたは複数の生物活性剤(例えば、疎水性活性成分)をさらに含む。本明細書中で使用される場合、「生物活性剤」という用語は、組織に影響を及ぼす有効量で投与したときに、ヒトまたはヒト以外の動物被験体に対して効果を有する任意の物質をいう。生物活性剤は、薬物分子または生物学的物質(例えば、ポリペプチド、炭水化物、糖タンパク質、免疫グロブリン、核酸)等の任意の種類の物質であってもよく、天然産物または人工的に産生されたものであってもよく、薬理学的、免疫学的、または代謝的等の任意のメカニズムによって作用してもよい。生物活性剤の種類の例としては、眼圧を改変する物質(例えば、酵素阻害剤)および抗血管新生剤が挙げられる。生物活性剤の特定の例としては、ステロイド(例えば、コルチコステロイド)、抗生物質、免疫抑制剤、免疫調節剤、タクロリムス、プラスミンアクチベーター、抗プラスミン、およびシクロスポリンAが挙げられる。諸実施形態では、生物活性剤は、眼感染を治療または予防するためのステロイドまたは抗生物質であり、例えば、プロスタグランジン類似体、β遮断薬、αアゴニスト、または炭酸脱水酵素阻害剤等の緑内障薬;ヒスタミン拮抗薬または非ステロイド性抗炎症薬等のアレルギー眼軽減剤;または散瞳剤である。残念ながら、いくつかの場合において、組成物に含まれる生物活性剤は、眼または上皮表面(例えば、シクロスポリンA)に対して刺激性または損傷性である可能性がある。組成物中の高分子量HAは、そのレオロジー特性および他の特性によって、眼の上皮等の上皮に対する組成物中の生物活性剤の刺激性および/または損傷性効果を軽減し、かつ/あるいは、当該効果から上皮を保護することができ、有利である(すなわち、高分子量HAなしで投与される場合、生物活性剤は、上皮表面に対してより刺激性であるか、またはより損傷性である)。
上記のように、本発明の組成物および方法において使用されるHAは、高分子量(HMW)HAである。諸実施形態では、流体のヒアルロン酸は、2.5m3/kgを超える固有粘度を有する。諸実施形態では、ヒアルロン酸は、2.9m3/kgを超える固有粘度を有する。
[η] = k ・ (Mrm)a
MrmはMDaの分子量であり
係数
k = 1.3327 ・ 10-4
および
a = 0.6691
kとaの値が最も予測的であることがわかっている。
「a」、「an」、「the」という用語、および本発明の文脈において(特に特許請求の範囲の文脈において)使用される同様の用語は、本明細書において特に示されない限り、または文脈によって明らかに矛盾しない限り、単数および複数の両方を包含すると解釈されるべきである。したがって、例えば、「細胞」または「化合物」という用語は、文脈によって特に示されない限り、または明確に矛盾しない限り、単数の細胞または単数の化合物および複数の細胞または複数の化合物の両方を包含すると解釈されるべきである。同様に、「または」という用語は、文脈によって明確に示されない限り、「および」を含むことが意図される。「e.g.(例えば)」という略語は、ラテン語の「exempli gratia」に由来し、本明細書において非限定的な例を示すために使用される。したがって、「e.g.(例えば)」という略語は、「for example(例えば)」という用語と同義である。
重度のドライアイ患者(ODISSEY主要基準による)を対象とした多施設共同多国籍前向き無作為化臨床試験が、9カ国12施設で実施されている。HYLAN M試験において、患者を2つの群に無作為化し、一方は以前に同定された最も有効な個々の患者処置にとどめ、他方は高分子量ヒアルロン酸点眼剤(保存剤を含まないヒアルロン酸ナトリウム点眼剤コンフォートシールド(Comfort Shield)(登録商標)(ドイツ、ミュンヘン、i.com medical GmbH))に切り替え、これは本明細書中の表1の実施形態に対応する。
Claims (78)
- 被験体の上皮表面にヒアルロン酸を修復または補充するための修復/補充方法であって、
組成物を前記被験体の前記上皮表面に局所投与することを含み、
前記組成物は、高分子量ヒアルロン酸、高分子量ヒアルロン酸類似体、またはそれらの組み合わせを含み、前記上皮表面は、ヒアルロン酸の量または機能の欠如を有する、
修復/補充方法。 - 請求項1に記載の修復/補充方法であって、
前記上皮表面は前記被験体における過敏反応の部位であり、前記組成物は過敏拒絶の開始前に、前記上皮表面に予防的に局所投与される
修復/補充方法。 - 請求項1に記載の修復/補充方法であって、
前記上皮表面は前記被験体における過敏反応の部位であり、前記組成物は過敏拒絶の開始後に前記上皮表面に治療的に局所投与される
修復/補充方法。 - 請求項2または3に記載の修復/補充方法であって、
前記過敏反応は、局所的である
修復/補充方法。 - 請求項2または3に記載の修復/補充方法であって、
前記過敏反応は、全身性である
修復/補充方法。 - 請求項1から5のいずれか1つに記載の修復/補充方法であって、
前記被験体は、アトピーを有する
修復/補充方法。 - 請求項1から6のいずれか1つに記載の修復/補充方法であって、
前記上皮表面は、身体の内部にある
修復/補充方法。 - 請求項1から7のいずれか1つに記載の修復/補充方法であって、
前記上皮表面は、体腔の内部を裏打ちする
修復/補充方法。 - 請求項1から6のいずれか1つに記載の修復/補充方法であって、
前記上皮表面は、身体の外側にある
修復/補充方法。 - 請求項1から6のいずれか1つに記載の修復/補充方法であって、
前記上皮表面は、皮膚の上皮である
修復/補充方法。 - 請求項1から8のいずれか1つに記載の修復/補充方法であって、
前記上皮表面は、粘膜の表面である
修復/補充方法。 - 請求項11に記載の修復/補充方法であって、
前記粘膜は、眼、耳、胃腸管(例えば、口、食道、胃、小腸、大腸、結腸、盲腸、直腸、または肛門)、気道(例えば、鼻、喉頭、気管、気管支樹、肺胞)、または泌尿生殖器(例えば、膀胱、尿管、尿道、腎臓、輸精管、外陰部、膣、子宮頸部、子宮、卵管)の粘膜である
修復/補充方法。 - 請求項1から6のいずれか1つに記載の修復/補充方法であって、
前記上皮表面は、眼表面(例えば、結膜または角膜の上皮)
修復/補充方法。 - 請求項1から6のいずれか1つに記載の修復/補充方法であって、
前記上皮表面は、眼以外の表面である
修復/補充方法。 - 請求項1から14のいずれか1つに記載の修復/補充方法であって、
前記組成物は、液体(例えば、流体、噴霧、ローション、エアロゾル)である
修復/補充方法。 - 請求項1から14のいずれか1つに記載の修復/補充方法であって、
前記組成物は、固体(例えば、錠剤、カプセル、顆粒、粉末、小袋、乾燥粉末吸入剤、チュアブル)である
修復/補充方法。 - 請求項1から14のいずれか1つに記載の修復/補充方法であって、
前記組成物は、半固体(例えば、クリーム、軟膏剤、ゲル、ゼリー、ペースト、軟膏、バルム、ムース、泡、経皮パッチ、坐剤)である
修復/補充方法。 - 請求項1から17のいずれか1つに記載の修復/補充方法であって、
前記組成物は、他の免疫調節剤、免疫抑制剤、または抗生物質を含有しない
修復/補充方法。 - 請求項1から18のいずれか1つに記載の修復/補充方法であって、
前記組成物は、他の生物活性剤を含有しない(例えば、疎水性活性成分を含有しない)
修復/補充方法。 - 請求項1から17のいずれか1つに記載の修復/補充方法であって、
前記組成物は、生物活性剤(例えば、疎水性活性成分)をさらに含む
修復/補充方法。 - 請求項20に記載の修復/補充方法であって、
前記生物活性剤は、静菌剤または殺菌剤を含む
修復/補充方法。 - 請求項20に記載の修復/補充方法であって、
前記生物活性剤は、免疫抑制剤(例えば、シクロスポリンA、タクロリムス、またはシロリムス等のT細胞阻害剤;代謝拮抗剤;アルキル化剤;インフリキシマブ、エタネルセプト、またはアジルマブ等のTNF阻害剤;リンパ球阻害剤;またはインターロイキン阻害剤);プロスタグランジン(レタノプロスト)、プロスタグランジン類似体、または眼圧を低下させる他の薬剤;ならびに抗ヒスタミンおよび/または肥満細胞安定剤(例えば、ケトチフェン)の中から選択される1つ以上の薬剤を含む
修復/補充方法。 - 請求項20に記載の修復/補充方法であって、
前記生物活性剤は免疫調節剤を含み、前記高分子量ヒアルロン酸は前記上皮表面の環境を前記免疫調節剤の活性をより促すものにし、前記免疫調節剤の作用を増強または促進する
修復/補充方法。 - 請求項22又は23に記載の修復/補充方法であって、
前記上皮表面は、眼表面である
修復/補充方法。 - 請求項20に記載の修復/補充方法であって、
前記生物活性剤は、抗炎症剤を含む
修復/補充方法。 - 請求項25に記載の修復/補充方法であって、
前記抗炎症剤は、グルココルチコイドまたは他のステロイド(例えば、プレドニゾン、酢酸コルチゾン、プレドニゾロン、メチルプレドニゾロン、デキサメタゾン、ベタメタゾン、トリアムシノロン、ベクロメタゾン、酢酸フルドロコルチゾン、酢酸デオキシコルチコステロン、アルドステロン)、非ステロイド性抗炎症薬(例えば、サリチレート、アリールアルカン酸、2−アリールプロピオン酸、N−アリールアントラニル酸、オキシカム、コキシブ、またはスルホナニリド)、Cox−2特異的阻害剤(例えば、バルデコキシブ、セレコキシブ、またはロフェコキシブ)、レフルノミド、金チオグルコース、金チオマート、オーロフィン、スルファサラジン、ヒドロキシクロロキニン、ミノサイクリンTNF−α結合タンパク質(例えば、インフリキシマブ、エタネルセプト、またはアダリムマブ)、アバタセプト、アナキンラ、インターフェロン−β、インターフェロン−γ、インターロイキン−2、アレルギーワクチン、抗ヒスタミン、抗ロイコトリエン、β作動薬、テオフィリン、抗コリン薬、抗生物質、タクロリムス、およびレチノイドからなる群から選択される抗炎症剤である
修復/補充方法。 - 請求項1から26のいずれか1つに記載の修復/補充方法であって、
前記組成物が、溶剤、共溶剤、粘滑剤、皮膚軟化剤、防腐剤、抗酸化剤、保湿剤、または可溶化剤のうちの1つ以上をさらに含む
修復/補充方法。 - 請求項20に記載の修復/補充方法であって、
前記上皮表面は眼表面を含み、前記生物活性剤は高分子量ヒアルロン酸および/または高分子量ヒアルロン酸類似体の非存在下で眼に対して刺激性または損傷性である
修復/補充方法。 - 請求項1から28のいずれか1つに記載の修復/補充方法であって、
前記組成物は、防腐剤または洗浄剤をさらに含む
修復/補充方法。 - 請求項29に記載の修復/補充方法であって、
前記防腐剤または洗浄剤が、眼に対して刺激性または損傷性である
修復/補充方法。 - 請求項1から30のいずれか1つに記載の修復/補充方法であって、
前記組成物は、前記被験体への異なる組成物の投与前、投与中、および/または投与後に投与され、前記異なる組成物は生物活性剤(例えば、疎水性活性成分)、防腐剤、洗浄剤、またはこれらの2つ以上の組み合わせを含む
修復/補充方法。 - 請求項31に記載の修復/補充方法であって、
前記生物活性剤は免疫調節剤を含み、前記高分子量ヒアルロン酸は前記上皮表面の環境を前記免疫調節剤の活性をより促すものにし、前記免疫調節剤の作用を増強または促進する
修復/補充方法。 - 請求項31または32に記載の修復/補充方法であって、
前記上皮表面は眼表面を含み、前記生物活性剤、防腐剤、洗浄剤、または組み合わせは、前記高分子量ヒアルロン酸および/または高分子量ヒアルロン酸類似体の非存在下で眼に対して刺激性または損傷性である
修復/補充方法。 - 請求項31に記載の修復/補充方法であって、
前記防腐剤または洗浄剤が化学防腐剤または酸化防腐剤である
修復/補充方法。 - 請求項30に記載の修復/補充方法であって、
前記保存剤または洗浄剤が、その影響を受けやすい微生物細胞を微生物細胞膜の脂質構造を破壊することによって死滅させ、それによって微生物細胞膜透過性を増大させるものである
修復/補充方法。 - 請求項30に記載の修復/補充方法であって、
前記上皮表面は眼表面を含み、前記保存剤または洗浄剤は、前記高分子量ヒアルロン酸および/または高分子量ヒアルロン酸類似体の非存在下で角膜組織に損傷を引き起こすものである
修復/補充方法。 - 請求項30に記載の修復/補充方法であって、
前記上皮表面は眼表面を含み、前記防腐剤または洗浄剤は第4級アンモニウム防腐剤(例えば、塩化ベンザルコニウム(BAK))、クロロブタノール、エデト酸二ナトリウム(EDTA)、ポリクワタナリウム-1(例えば、ポリクアッド(Polyquad)(商標)防腐剤)、安定化酸化剤(例えば、安定化オキシクロロ錯体(例えば、ピュライト(Purite)(商標)防腐剤))、イオンバッファ防腐剤(例えば、ソフジア(sofZia)(商標)防腐剤)、ポリヘキサメチレンビグアニド(PHMB)、過ホウ酸ナトリウム(例えば、ジェンアクア(GenAqua)(商標)防腐剤)、およびソルビン酸塩からなる群から選択される
修復/補充方法。 - 請求項1から28のいずれか1つに記載の修復/補充方法であって、
前記組成物は、防腐剤をさらに含まない(すなわち、前記組成物は防腐剤フリーである)
修復/補充方法。 - 請求項1から38のいずれか1つに記載の修復/補充方法であって、
前記組成物は、追加のグリコサミノグリカン(GAG)、電解質(例えば、塩化ナトリウム)、緩衝液(例えば、リン酸緩衝液)、またはこれらの2つ以上の組み合わせをさらに含む
修復/補充方法。 - 請求項1から39のいずれか1つに記載の修復/補充方法であって、
前記組成物は、流体であり、点滴剤または洗浄剤として前記上皮表面に直接局所投与される
修復/補充方法。 - 請求項40に記載の修復/補充方法であって、
前記流体の1から3滴が、1日に1から3回投与される
修復/補充方法。 - 請求項1から39のいずれか1つに記載の修復/補充方法であって、
前記組成物は、前記上皮表面に局所投与される送達剤(例えば、前記組成物でコーティングされ、および/または前記上皮表面上に前記組成物を放出する粒子)によって、前記上皮表面に間接的に局所投与される
修復/補充方法。 - 請求項1から42のいずれか1つに記載の修復/補充方法であって、
前記組成物は、浴槽およびシャワー製品、ベビーおよびキッドケア製品、サンケア製品、シャンプー、ヘアコンディション、ボディローション、固体または液状石けん、ヘアスタイリング製品、シェービングクリーム、アフターシェービング製品、ハンドおよびネイルクリーム、フェースクリーム、フェースクレンジングローション、コロン、マウスウォッシュ、または練り歯磨きから選択される健康および美容製品である
修復/補充方法。 - 請求項1から43のいずれか1つに記載の修復/補充方法であって、
前記組成物は、化粧品である
修復/補充方法。 - 請求項44に記載の修復/補充方法であって、
前記化粧品は、ファンデーション、マスカラ、アイシャドウ、アイライナー、ピール、スクラブ、フェースマスク、皮膚タイター、トナー、ボディバター、サンケア製品、シャワーゲル、アイクリーム、ハンドおよびキューティクルクリーム、またはメイクアップ粉である
修復/補充方法。 - 請求項1から45のいずれか1つに記載の修復/補充方法であって、
前記組成物は、アプリケータを用いて投与される
修復/補充方法。 - 請求項46に記載の修復/補充方法であって、
前記アプリケータは、ドロッパー、スワブ、化粧パッド、ワイプ、ワイプスティック、タオレット、スポンジ、ガーゼ、パフ、ワンド、または接着性もしくは非接着性の包帯の中から選択される
修復/補充方法。 - 請求項1から47のいずれか1つに記載の修復/補充方法であって、
前記高分子量ヒアルロン酸および/または高分子量ヒアルロン酸類似体は、2.5m3/kgを超える固有粘度を有する
修復/補充方法。 - 請求項1から48のいずれか1つに記載の修復/補充方法であって、
前記高分子量ヒアルロン酸および/または高分子量ヒアルロン酸類似体は、2.9m3/kgを超える固有粘度を有する
修復/補充方法。 - 請求項1から49のいずれか1つに記載の修復/補充方法であって、
前記上皮表面は眼表面を含み、前記組成物は0.2%w/v未満の高分子量ヒアルロン酸および/または高分子量ヒアルロン酸類似体の濃度を有する
修復/補充方法。 - 請求項1から50のいずれか1つに記載の修復/補充方法であって、
前記上皮表面は皮膚を含み、前記組成物は0.2%から3.0%w/vの高分子量ヒアルロン酸および/または高分子量ヒアルロン酸類似体の濃度を有する
修復/補充方法。 - 請求項1から51のいずれか1つに記載の修復/補充方法であって、
前記ヒアルロン酸は、少なくとも300万ドルトンの分子量を有する
修復/補充方法。 - 請求項1から52のいずれか1つに記載の修復/補充方法であって、
前記ヒアルロン酸は、300万から400万ドルトンの範囲の分子量を有する
修復/補充方法。 - 請求項1から53のいずれか1つに記載の修復/補充方法であって、
前記過敏反応は、結膜炎、鼻結膜炎、内因性アトピー性皮膚炎(すなわち非IgE関連性)、外因性アトピー性皮膚炎(すなわちIgE関連湿疹)、免疫介在性蕁麻疹、免疫介在性血管性浮腫、急性(IgE介在性)ラテックスアレルギー、アレルギー性喘息、アレルギー性気管支肺アスペルギルス症のIgE介在性成分、アレルギー性鼻炎(花粉症)、好酸球性胃腸炎(EGE)、および好酸球性大腸炎(ECO)の中から選択されるアトピー性障害と関連している
修復/補充方法。 - 請求項1から54のいずれか1つに記載の修復/補充方法であって、
前記被験体は、アトピー性皮膚炎、アレルギー性喘息、およびアレルギー性鼻炎のうちの1つ以上を有する
修復/補充方法。 - 請求項1から55のいずれか1つに記載の修復/補充方法であって、
前記被験体は、アトピーに関連する遺伝的変異(例えば、多型)を有する
修復/補充方法。 - 請求項1から56のいずれか1つに記載の修復/補充方法であって、
前記上皮表面は、咬傷または刺傷に対する(例えば、毒等の昆虫分泌物からの)アレルギー反応である過敏反応の部位である
修復/補充方法。 - 請求項1から57のいずれか1つに記載の修復/補充方法であって、
前記上皮表面は、動物のふけ、ほこり、チリダニの糞、カビ、および花粉の中から選択される空中または非空中物質によって誘発される過敏反応の部位である
修復/補充方法。 - 請求項1から58のいずれか1つに記載の修復/補充方法であって、
前記上皮表面は、以下の症状:蕁麻疹、膨疹、鱗屑、眼、鼻、または皮膚のかゆみ、鼻づまり、眼の充血、鼻水、副鼻腔の痛み、副鼻腔の腫れ、およびくしゃみのうちの1つ以上によって特徴付けられる過敏反応の部位である
修復/補充方法。 - 請求項1から59のいずれか1つに記載の修復/補充方法であって、
前記被験体は、円錐角膜を有する眼を有し、前記組成物は前記眼の眼表面に局所投与される
修復/補充方法。 - 請求項1から60のいずれか1つに記載の修復/補充方法であって、
前記組成物は、高分子量ヒアルロン酸と高分子量ヒアルロン酸類似体との組み合わせを含む
修復/補充方法。 - 請求項1から61のいずれか1つに記載の修復/補充方法であって、
前記組成物は、高分子量ヒアルロン酸を含み、高分子量ヒアルロン酸類似体を含まない
修復/補充方法。 - 請求項1から62のいずれか1つに記載の修復/補充方法であって、
前記高分子量ヒアルロン酸は架橋されている
修復/補充方法。 - 請求項1から15、17から50および52から63のいずれか1つに記載の修復/補充方法であって、
前記組成物は、0.1から0.19%w/vの濃度を有する高分子量ヒアルロン酸を含む
修復/補充方法。 - 請求項64に記載の修復/補充方法であって、
前記組成物は、
a)6.8から7.6のpHと、
b)240から330mosmol/kgの浸透圧と、
c)7.6から10.5g/lのNaCl濃度と、
d)1.0から1.4mmol/lのリン酸塩濃度と、
を有する
修復/補充方法。 - 請求項64または65に記載の修復/補充方法であって、
前記組成物は、目に見える不純物を含まない無色透明の溶液である
修復/補充方法。 - 請求項64から66のいずれか1つに記載の修復/補充方法であって、
前記組成物は、無菌である
修復/補充方法。 - 請求項1に記載の修復/補充方法であって、
前記組成物は、コンフォートシールド(Comfort Shield)(登録商標)保存剤を含まないヒアルロン酸ナトリウム点眼剤である
修復/補充方法。 - 請求項1から68のいずれか1つに記載の組成物で前処理された、または前記組成物を含有するアプリケータ。
- 請求項69に記載のアプリケータであって、
前記アプリケータは、綿棒、化粧パッド、拭き取り布、拭き取りスティック、タオレット、スポンジ、ガーゼ、パフ、ワンド、ブラシ、櫛、ドロッパ、接着性もしくは非接着性包帯、またはコンタクトレンズである
アプリケータ。 - 請求項1から68のいずれか1つに記載の組成物を含むキット。
- 請求項71に記載のキットであって、
アプリケータをさらに含む
キット。 - 請求項71または72に記載のキットであって、
前記組成物を含有する容器をさらに含む
キット。 - 請求項72または73に記載のキットであって、
前記アプリケータは、前記組成物で前処理されるか、または前記組成物を含む
キット。 - 請求項72から74のいずれか1つに記載のキットであって、
前記アプリケータは、綿棒、化粧パッド、拭き取り布、拭き取りスティック、タオレット、スポンジ、ガーゼ、パフ、ワンド、ブラシ、櫛、ドロッパ、または接着性もしくは非接着性包帯である
キット。 - 請求項73に記載のキットであって、
前記容器は、ボトル、管、花瓶、または小袋である
キット。 - 請求項73または76に記載のキットであって、
前記容器は、ポンプ、スプレー、またはキャップから選択されるクロージャを含む
キット。 - 請求項71から77のいずれか1つに記載のキットであって、
前記組成物を上皮表面に局所投与することによって前記組成物を前記上皮表面に適用するための説明書、および、必要に応じて、ヒアルロン酸の量または機能が欠如している上皮表面にヒアルロン酸を修復または補充するための説明書をさらに含む
キット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862659180P | 2018-04-18 | 2018-04-18 | |
US62/659,180 | 2018-04-18 | ||
PCT/EP2019/059962 WO2019202015A1 (en) | 2018-04-18 | 2019-04-17 | High molecular weight hyaluronic acid for enhancing epithelial survival and reconstitution of body surfaces |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021522189A true JP2021522189A (ja) | 2021-08-30 |
JPWO2019202015A5 JPWO2019202015A5 (ja) | 2022-04-25 |
Family
ID=66251769
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020557324A Pending JP2021522189A (ja) | 2018-04-18 | 2019-04-17 | 上皮の生存と体表面の再構成を高めるための高分子量ヒアルロン酸 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20210145862A1 (ja) |
EP (1) | EP3781116A1 (ja) |
JP (1) | JP2021522189A (ja) |
KR (1) | KR20210003168A (ja) |
CN (1) | CN112384190A (ja) |
CA (1) | CA3097470A1 (ja) |
EA (1) | EA202092471A1 (ja) |
WO (1) | WO2019202015A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102500714B1 (ko) * | 2022-09-30 | 2023-02-17 | 주식회사 학메디칼 | 코로나 바이러스 감염 진단을 위한 검체 채취용 조성물 및 이를 이용한 코로나바이러스 감염 진단 키트 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10786448B2 (en) | 2018-01-18 | 2020-09-29 | Christian Arnold | Chewing gum composition comprising polyhexanide |
CH716227B1 (it) * | 2020-04-16 | 2020-11-30 | Contrad Swiss Sa | Composizione in gel per applicazione topica per la riduzione dell'infiammazione locale. |
EP4167965A1 (en) * | 2020-06-21 | 2023-04-26 | i.com Medical GmbH | Use of high molecular weight hyaluronic acid as ocular transporting vehicle |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08505388A (ja) * | 1992-12-30 | 1996-06-11 | パテント・バイオファーマスーティックス・インコーポレーテッド | ヒアルロン酸−尿素医薬組成物およびその使用 |
WO1998029125A1 (fr) * | 1996-12-27 | 1998-07-09 | Seikagaku Corporation | Remedes contre des troubles de la vessie |
JP2002522570A (ja) * | 1998-08-05 | 2002-07-23 | ジャスパー、リミテッド、ライアビリティ、カンパニー | ヒアルロン酸と天然型アミノ酸との反応生成物、ならびに化粧品および医薬組成物への使用 |
JP2006501133A (ja) * | 2001-12-12 | 2006-01-12 | ウーアザファルマ アールツナイミッテル ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント カンパニー カーゲー | 眼科学および鼻科学における適用のための薬学的組成物 |
WO2008072905A1 (en) * | 2006-12-13 | 2008-06-19 | Lg Life Sciences, Ltd. | Composition comprising hyaluronic acid and/or its salts for treatment of atopic dermatitis |
JP2009510091A (ja) * | 2005-09-27 | 2009-03-12 | ティッシュテク・インコーポレーテッド | 羊膜調製物及び精製組成物及びその使用方法 |
EP2070518A2 (en) * | 2006-07-25 | 2009-06-17 | Osmotica Corp. | Ophthalmic solutions |
WO2012119261A1 (en) * | 2011-03-10 | 2012-09-13 | Biocia Inc. | Enhanced artificial mucus composition comprising hyaluronan for the treatment of rhinitis |
JP2013522283A (ja) * | 2010-03-12 | 2013-06-13 | アラーガン・アンデュストリー・ソシエテ・パール・アクシオン・サンプリフィエ | 皮膚状態を改善するための流体組成物 |
JP2014502642A (ja) * | 2011-07-07 | 2014-02-03 | アイホル コーポレーション | 炎症関連障害の治療および予防に使用するための組成物 |
EP3056195A1 (en) * | 2015-02-13 | 2016-08-17 | Vision:Organic GmbH | Compositions comprising hyaluronic acid and beta-glucan for topical applications in oral cavity |
US20170014339A1 (en) * | 2015-07-17 | 2017-01-19 | i.com medical GmbH | Tear Substitute, Fluid for Being Used as a Tear Substitute, and Method for Producing a Tear Substitute |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
EP0778776A1 (en) * | 1994-08-30 | 1997-06-18 | Hyal Pharmaceutical Corporation | Hyaluronic acid and derivatives for modulation of cellular activity |
DE102009008940A1 (de) * | 2009-02-13 | 2010-08-19 | Rolf Ludl | Hautpflegende Kombination aus Hyaluronsäuregel und Creme in separaten Zubereitungen |
EP2567689A1 (en) * | 2011-09-12 | 2013-03-13 | Visiotact Pharma | Ophthtalmic compositions comprising prostaglandin F2 alpha derivatives and hyaluronic acid |
CN104666139A (zh) * | 2013-11-27 | 2015-06-03 | 丁阿维 | 一种复合驱蚊爽肤水及其制备方法 |
-
2019
- 2019-04-17 US US17/048,436 patent/US20210145862A1/en active Pending
- 2019-04-17 JP JP2020557324A patent/JP2021522189A/ja active Pending
- 2019-04-17 WO PCT/EP2019/059962 patent/WO2019202015A1/en unknown
- 2019-04-17 EP EP19719230.5A patent/EP3781116A1/en active Pending
- 2019-04-17 CA CA3097470A patent/CA3097470A1/en active Pending
- 2019-04-17 CN CN201980039670.5A patent/CN112384190A/zh active Pending
- 2019-04-17 KR KR1020207033027A patent/KR20210003168A/ko not_active Application Discontinuation
- 2019-04-17 EA EA202092471A patent/EA202092471A1/ru unknown
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08505388A (ja) * | 1992-12-30 | 1996-06-11 | パテント・バイオファーマスーティックス・インコーポレーテッド | ヒアルロン酸−尿素医薬組成物およびその使用 |
WO1998029125A1 (fr) * | 1996-12-27 | 1998-07-09 | Seikagaku Corporation | Remedes contre des troubles de la vessie |
JP2002522570A (ja) * | 1998-08-05 | 2002-07-23 | ジャスパー、リミテッド、ライアビリティ、カンパニー | ヒアルロン酸と天然型アミノ酸との反応生成物、ならびに化粧品および医薬組成物への使用 |
JP2006501133A (ja) * | 2001-12-12 | 2006-01-12 | ウーアザファルマ アールツナイミッテル ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント カンパニー カーゲー | 眼科学および鼻科学における適用のための薬学的組成物 |
JP2009510091A (ja) * | 2005-09-27 | 2009-03-12 | ティッシュテク・インコーポレーテッド | 羊膜調製物及び精製組成物及びその使用方法 |
EP2070518A2 (en) * | 2006-07-25 | 2009-06-17 | Osmotica Corp. | Ophthalmic solutions |
WO2008072905A1 (en) * | 2006-12-13 | 2008-06-19 | Lg Life Sciences, Ltd. | Composition comprising hyaluronic acid and/or its salts for treatment of atopic dermatitis |
JP2013522283A (ja) * | 2010-03-12 | 2013-06-13 | アラーガン・アンデュストリー・ソシエテ・パール・アクシオン・サンプリフィエ | 皮膚状態を改善するための流体組成物 |
WO2012119261A1 (en) * | 2011-03-10 | 2012-09-13 | Biocia Inc. | Enhanced artificial mucus composition comprising hyaluronan for the treatment of rhinitis |
JP2014502642A (ja) * | 2011-07-07 | 2014-02-03 | アイホル コーポレーション | 炎症関連障害の治療および予防に使用するための組成物 |
EP3056195A1 (en) * | 2015-02-13 | 2016-08-17 | Vision:Organic GmbH | Compositions comprising hyaluronic acid and beta-glucan for topical applications in oral cavity |
US20170014339A1 (en) * | 2015-07-17 | 2017-01-19 | i.com medical GmbH | Tear Substitute, Fluid for Being Used as a Tear Substitute, and Method for Producing a Tear Substitute |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102500714B1 (ko) * | 2022-09-30 | 2023-02-17 | 주식회사 학메디칼 | 코로나 바이러스 감염 진단을 위한 검체 채취용 조성물 및 이를 이용한 코로나바이러스 감염 진단 키트 |
Also Published As
Publication number | Publication date |
---|---|
US20210145862A1 (en) | 2021-05-20 |
KR20210003168A (ko) | 2021-01-11 |
CN112384190A (zh) | 2021-02-19 |
EP3781116A1 (en) | 2021-02-24 |
CA3097470A1 (en) | 2019-10-24 |
EA202092471A1 (ru) | 2021-03-25 |
WO2019202015A1 (en) | 2019-10-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2021522189A (ja) | 上皮の生存と体表面の再構成を高めるための高分子量ヒアルロン酸 | |
JP2020502197A (ja) | ドライアイ疾患の治療のための眼科用組成物 | |
US11413323B2 (en) | Ophthalmic composition for treatment of dry eye disease | |
CA3016759A1 (en) | Treatment of allergic eye conditions with cyclodextrins | |
JP6315755B2 (ja) | 異物感緩和点眼剤 | |
JP2019532105A (ja) | 角結膜のホメオスタシスを確立、回復及び維持するための方法 | |
SA521430043B1 (ar) | صياغات من المركب 4-(7- هيدروكسي-2- أيزوبروبيل-4- أوكسو-4h- كوينازولين-3- يل) - بنزونيتريل | |
JP6607976B2 (ja) | 異物感緩和点眼剤 | |
Kumar et al. | Efficacy and Adverse Effects of Topical Latanoprost with Respect to Preservative in Patients of POAG. | |
CN112292135A (zh) | 用于治疗和预防严重眼表疾病的高分子量透明质酸 | |
JP2023530189A (ja) | 高眼圧症および緑内障の治療および予防のためのヒアルロン酸に基づく製剤 | |
EA046057B1 (ru) | Высокомолекулярная гиалуроновая кислота для лечения и предупреждения тяжелого заболевания глазной поверхности | |
US20210369764A1 (en) | Hyaluronic acid for relief of idiopathic ocular pain | |
JP2021105065A (ja) | 異物感緩和点眼剤 | |
CN109789182A (zh) | 治疗干眼综合征的方法 | |
TomiT et al. | Clinical Study Influence of BAK-Preserved Prostaglandin Analog Treatment on the Ocular Surface Health in Patients with Newly Diagnosed Primary Open-Angle Glaucoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220414 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220414 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20220414 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230215 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230221 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230516 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230719 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230821 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231017 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240112 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240417 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20240417 |